Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. AALL1731 is a phase III randomized trial to determine if the addition of two nonsequential cycles of blinatumomab to chemotherapy improves disease-free survival in children with NCl standard-risk B-cell ALL (B-ALL). Results were presented at the 2024 ASH Annual Meeting & Exposition.
